Tag: immune checkpoint inhibitors (ICI)

Click to read the study in the European Journal of Cancer.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.  Evidence Rating Level: 1 (Excellent) Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...
1. The glucocorticoid-induced TNF receptor-related protein agonist, BMS-986156, is safe and tolerable as monotherapy and in combination with nivolumab. Evidence Rating Level: 2 (Good) Although immune checkpoint inhibitors (ICI) have shown clinical efficacy in a wide variety of cancers, a significant portion remain unresponsive to checkpoint blockade. Therefore, new strategies for...